Vaccines aren't enough – working on a way to stop the polio virus for good

December 7, 2017 by Keith Grehan, The Conversation
Credit: Shutterstock

There were just 74 cases of polio reported worldwide in 2015. Thanks to a global vaccination drive, this crippling disease, which once affected hundreds of thousands of people a year, is now on the verge of extinction. The World Health Organisation estimates its eradication programme has saved around 5m people from a lifetime of paralysis.

But what happens when is finally gone? To make sure it does not come back, worldwide vaccination will have to continue. To keep producing a vaccine with current technology, we will have to retain enormous live stocks of the . This will run the risk of the virus escaping into the wild and restarting the disease – the opposite of what the vaccination programme is designed to do.

My colleagues and I are part of an international effort to come up with a new way of producing a polio vaccine that does not rely on us keeping the virus alive. The basic principle of a vaccine is to expose the body to a molecule known as an antigen that stimulates the immune system into fighting the related disease. This way, when the body encounters the actual disease, it has learnt how to react to it.

Vaccines have been in use in one form or another since the 10th century when ancient Chinese healers exposed healthy patients to powdered scabs from smallpox sufferers. Modern vaccine development relies on more controlled and safer forms of antigen exposure. In the case of virus-carried diseases like polio, the antigen is most often a weakened or deactivated version of the virus, made from a live strain.

One alternative idea is to develop a virus-like particle (VLP) assembled from the proteins that make up the coat or "capsid" of the virus. They contain no from the virus and so are sometimes called "empty capsids". This makes them safe to manufacture and use without risk of spreading the actual disease. Scientists have already used this method to develop successful vaccines against hepatitis B and human papillomavirus (HPV)

To create a VLP for poliovirus, we would like to use empty capsids that are made naturally during its normal growth cycle. The problem is that, without any genetic material inside them, these are structures are unstable when exposed to heat.

Our research group has tried a number of ways to create stable capsids for the VLPs. Our first step was to select strains of poliovirus that were inherently more resistant to heat. We repeatedly heated a sample of the virus to increasing temperatures and then exposed it to cultured cells. This enabled us to identify that were still infectious to the cells – and therefore stable – even when heated up to 57℃.

To further demonstrate these were more stable, we used a test known as a particle stability thermal release assay (PaSTRy). This involves staining the molecules that make up the virus's capsid, and the genetic material, inside with dyes that fluoresce (give off light) when exposed to the environment. Our more stable viruses didn't fluoresce after they had been heated, which showed they were still in tact.

We then isolated the mutations that made these strains so resistant to heat and used them as a model to produce empty capsids that had the desired stability. Other researchers in our group have also identified mutations that reduce the capsids' sensitivity to temperature changes and so could also generate more stable VLPs. Some of the mutant strains are proving to be even more stable than the inactivated polio vaccine currently in use.

Making the vaccine

We still need to work out the best way to use these VLPs to produce a viable . In particular, we want to develop a novel system that will produce VLPs in large numbers and with a minimum of specialised equipment. Several different systems are currently being studied including yeast, insect or plant cells. In most cases, we use a type of DNA molecule called plasmids to drive the yeast, plant or bacterial cells to produce these proteins. The VLPs are then assembled from these proteins either within the cell or during the purification process.

At the University of Leeds, we are focused on using a yeast species, Pichia pistoris. Yeast has a significant advantage over other systems because it can be grown in large quantities using fermenters. This makes it relatively simple to use them to produce vaccines on a large scale, something that has already been demonstrated for the Chikungunya .

Once we can replicate this process for the and manufacture it on a large scale, we can start looking forward to the day when we are confident the disease has been banished for good.

Explore further: Scientists prove new approach to Polio vaccines works

Related Stories

Scientists prove new approach to Polio vaccines works

February 1, 2017
Scientists have identified new ways to provide vaccines against polio, which do not require the growth of live virus for their manufacture.

Plant-produced polio vaccines could help eradicate age old disease

August 15, 2017
Plants have been used to produce a new vaccine against poliovirus in what is hoped to be a major step towards global eradication of the disease.

New technique could enable safer production of polio vaccines

January 19, 2017
A new method to produce a stable fragment of poliovirus could enable safer production of vaccines, according to a study published in PLOS Pathogens.

Syria sees first polio cases in three years: WHO

June 9, 2017
Three new cases of polio have been recorded in Syria in the first outbreak of the virus in the country since 2014, the World Health Organization and a partner initiative said.

Creating safer polio vaccine strains for the post-eradication era

December 31, 2015
While the goal of polio virus eradication is in sight, there are concerns about post-eradication manufacturing and stockpiling vaccine stores containing live virus that could escape and repopulate the environment. A study ...

WHO urges polio vaccine dose cut amid global shortage

April 28, 2017
Faced with a shortage of polio vaccine, the World Health Organization urged countries Friday to resort to smaller, fractional doses to ward off outbreaks of the crippling disease.

Recommended for you

More frequent checks control MRSA in newborns, but can hospitals afford them?

May 22, 2018
The more often a hospital can check its newborns for deadly MRSA germs, the more likely it will be that they are contained, according to a new study.

Could we predict the next Ebola outbreak by tracking the migratory patterns of bats?

May 22, 2018
Javier Buceta, associate professor of bioengineering, Paolo Bocchini, associate professor of civil and environmental engineering, and postdoctoral student Graziano Fiorillo of Lehigh University have created a modeling framework ...

Helping preterm infants grow bigger kidneys would prevent kidney disease later in life

May 21, 2018
Nephrons are the microscopic blood-filtering units inside our kidneys that convert waste products into urine, regulate our electrolyte levels and our blood pressure.

Kidney docs worry over no dialysis for undocumented immigrants

May 21, 2018
(HealthDay)—Undocumented immigrants in the United States are often denied treatment for kidney failure until they have a life-threatening emergency. Now a new study finds that the doctors and nurses who treat them are frustrated ...

Clues found to early lung transplant failure

May 21, 2018
Among organ transplant patients, those receiving new lungs face a higher rate of organ failure and death compared with people undergoing heart, kidney and liver transplants. One of the culprits is inflammation that damages ...

How to ethically conduct clinical research during public health emergencies

May 21, 2018
Following the 2014-2015 Ebola outbreak in West Africa, the U.S. National Academy of Sciences, Engineering and Medicine established a committee to assess the clinical trials conducted in Guinea, Sierra Leone and Liberia. In ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.